Skip to content
18 November · 06:30 UTCFollow AstraZeneca by emailFollow

AZN · story · 17 November – 18 November

AstraZeneca wins several regulatory approvals

AstraZeneca · 8 headlines from 7 outlets, from 17 November 2026 to 18 November 2026.

The story

+9.3strongly positive
Headlines8
Outlets7
Days217 November – 18 November

Round-ups cover several AstraZeneca approvals spanning rare disease, bladder cancer and blood pressure.

The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

How each outlet covered it · 7 outlets

Every outlet, by impact on the tone

Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.

Source: MarketFrame news analysis

Every outlet, by impact on the tone. Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone. Source: MarketFrame news analysis
outletAverage tone
Kalkine Media7.5
Business Weekly10.0
Proactive Investors UK10.0
Benzinga10.0
London South East9.2
DirectorsTalk Interviews9.2
Moomoo7.5
OutletHeadlinesAverage tone
Kalkine Media2+7.5
Business Weekly1+10.0
Proactive Investors UK1+10.0
Benzinga1+10.0
London South East1+9.2
DirectorsTalk Interviews1+9.2
Moomoo1+7.5

One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.

Day by day · 2 days, strongest headlines first

Wednesday 18 November 20263 headlines · Articles describe approvals AstraZeneca received for cardiovascular, cancer and rare disease treatments.+8.6
ToneWhat the article reported, and why it scored that waySource
+10.0Multiple approvals across several therapy areas.Business Weekly (opens the article) ↗
+8.3New US and EU approvals secured during the week.Kalkine Media (opens the article) ↗
+7.5Two regulatory approvals in one day, with evidence comparison.Moomoo (opens the article) ↗
Tuesday 17 November 20265 headlines · Round-ups cover several AstraZeneca approvals spanning rare disease, bladder cancer and blood pressure.+9.7
ToneWhat the article reported, and why it scored that waySource
+10.0Four regulatory successes across several areas.Proactive Investors UK (opens the article) ↗
+10.0Several approvals covering bladder cancer and a rare disease.Benzinga (opens the article) ↗
+9.2Briefing highlights its regulatory successes.London South East (opens the article) ↗
+9.2Progress across three treatment areas.DirectorsTalk Interviews (opens the article) ↗
+6.7General positive coverage of new medicines progress.Kalkine Media (opens the article) ↗

Follow by email

A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 18 November · 867 headlines · 94 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt